Real-time enrollment status for this hereditary transthyretin-mediated amyloidosis with polyneuropathy clinical trial
Current Status
Recruiting
Checked: August 27, 2026 at 6:09 PM UTC
| NCT Number | NCT07223203 |
| Recruiting Status | Recruiting |
| Condition | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy |
| Phase | PHASE3 |
| Target Enrollment | 125 participants |
| Active Locations | 10 sites in the US |
| Sponsor | Alnylam Pharmaceuticals |
| Last Updated on CT.gov | August 14, 2026 (1 week ago) |
As of August 27, 2026: Clinical trial NCT07223203 is currently recruiting participants. This phase3 study for hereditary transthyretin-mediated amyloidosis with polyneuropathy is actively seeking new participants at 10 locations across the United States. The study is sponsored by Alnylam Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07223203 is actively recruiting participants as of August 27, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 10 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07223203 was last updated 1 week ago (August 14, 2026). HelloStudys verifies this status automatically.